|
|
Dual-Acting Receptor Antagonist Reduces Systolic Blood Pressure: No Safety Signals Raised in Phase 2
|
| Link ID |
5869 |
| Title |
Dual-Acting Receptor Antagonist Reduces Systolic Blood Pressure: No Safety Signals Raised in Phase 2 |
| Url |
http://www.medscape.com/viewarticle/574699?src=rss |
| Description |
The drug, designed to achieve blockade of the endothelin and angiotensin receptors, reduced ambulatory systolic blood pressure almost 15 mm Hg at the highest dose and was safe and well tolerated in a small study of hypertensive patients, report investigators. Heartwire |
| Category |
Articles > Cardiology |
| Keywords |
|
| Date |
May 20, 2008 |
| Contact Name |
|
| Email |
|
Write a Review
Add to My Favorite
Refer it to Friend
Report Broken Link
|
|
Other links at Articles > Cardiology |
| 1. |
ACC 2008: The Future of Managing Dyslipidemia
|
|
|
ACC.08: Statins may be wonder drugs, but they still leave a significant percentage of patients at risk -- so the latest clinical trial and research results will be good news for treating dyslipidemia. Medscape Cardiology
|
| 3. |
AHA 2008: FIT HEART: Novel Family-Based Intervention a Good Idea, But Better Methods Needed
|
|
|
A new study in which the family members of patients hospitalized for cardiovascular disease were given CVD risk screening and lifestyle advice has shown that it is useful to take advantage of such "motivational moments." But the results could be improved upon, illustrating that it is difficult to change behavior in the "toxic environment" of the US, said the discussant. She stressed that better interventions--such as adopting the Mediterranean diet--are urgently needed. Heartwire
|
|
|
